Esketamine on Postoperative Sleep Disturbance of Patients Undergoing Spinal Surgery: A Randomized Controlled Trial

What this Trial Is About

This research aims to evaluate how intraoperative esketamine infusion affects postoperative sleep disturbance (PSD) in patients undergoing spinal surgery. It specifically investigates whether esketamine can influence the incidence of PSD, sleep quality, pain, anxiety, and depression after surgery. The study involves adult patients aged 18 to 65 scheduled for elective spinal surgery under general anesthesia at Beijing Tiantan Hospital. Participants are randomly assigned to receive either esketamine or saline infusion during spinal surgery. Esketamine is given at a dose of 0.3 mg/kg/h dissolved in normal saline, infused throughout the surgery. Both groups receive total intravenous anesthesia maintained with propofol and remifentanil, guided by the bispectral index to keep anesthesia depth between 40 and 60. The study is double-blind, meaning neither participants nor researchers know which infusion is given. During the study, researchers will monitor the incidence of postoperative sleep disturbance within the first three days after surgery. They will also assess sleep quality using sleep monitoring equipment on postoperative days 1 and 3, measure pain scores and analgesic use within 72 hours, and evaluate anxiety and depression levels using the hospital anxiety and depression scale. Adverse events and safety will be tracked throughout. Participation lasts through these early postoperative days with careful monitoring of sleep and recovery.

Esketamine on Postoperative Sleep Disturbance of Patients Undergoing Spinal Surgery